Target intelligence / Profile preview

PRKAG2 antisense RNA 1 (PRKAG2-AS1)

Target: PRKAG2-AS1
Molecular classification: Long non-coding RNA, Antisense RNA, Other

Overview

PRKAG2 antisense RNA 1 (PRKAG2-AS1) is a long non-coding RNA transcribed antisense to the PRKAG2 gene, implicated in the regulation of gene expression at the transcriptional or post-transcriptional level. It is overexpressed in multiple cancer types, including hepatocellular carcinoma, colon adenocarcinoma, advanced prostate cancer, and esophageal squamous cell carcinoma. High PRKAG2-AS1 expression correlates with poor prognosis and increased malignancy in cancer and is a promising prognostic biomarker as well as a potential therapeutic target due to its regulation of oncogenic pathways, particularly via miR-502-3p/BICD2 signaling

Other names: PRKAG2-AS1PRKAG2 antisense RNA 1

Mechanism of action

Silencing or inhibiting PRKAG2-AS1 leads to suppression of oncogenic traits (proliferation, migration, invasion) in cancer cells, likely via regulation of the miR-502-3p/BICD2 axis and modulation of downstream genes involved in EMT

Biological functions

Regulation of gene expression (specifically, PRKAG2)Promotes cancer cell proliferation, migration, and invasionFunctions as a competing endogenous RNA, binding microRNAs such as miR-502-3p and regulating the BICD2 axis in hepatocellular carcinomaModulation of epithelial-to-mesenchymal transition (EMT) markers

Disease associations

Cancer (notably hepatocellular carcinoma, colon adenocarcinoma, prostate cancer, esophageal squamous cell carcinoma)

Safety considerations

No known safety concerns or therapeutic challenges specifically documented for directly targeting PRKAG2-AS1; clinical experience is limited as this is an emerging target

Interacting drugs

None currently known or reported

Biomarkers

PRKAG2-AS1 expression in tissue may serve as a prognostic biomarker for disease-free and overall survival in hepatocellular carcinoma and possibly other cancers

Beyond the preview

Go deeper on PRKAG2 antisense RNA 1 (PRKAG2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRKAG2 antisense RNA 1 (PRKAG2-AS1).

Explore the full profile